CVMP meeting highlights, 14-16 July 2026: marketing authorisation and variation opinions

The Committee adopted a positive opinion for a marketing authorisation forBexatilfor the reduction of hyperglycaemia in cats with diabetes mellitus not previously treated with insulin. The Committee adopted a positive opinion for a variation forMometamax Ultrato implement the outcome of the MAH's signal management process to include ‘deafness’, ‘impaired hearing’, ‘application site inflammation’ and ‘application site pruritus’ as ‘very rare’ adverse events. The Committee adopted a positive opinion for a variation forCimalgexto implement the outcome of the MAH's signal management process to change the frequency of the adverse events ‘elevated renal parameters’ and ‘renal failure’ from ‘very rare’ to ‘rare’.